| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
| ln Vitro |
Aminoxyacetic acid hemihydrochloride (AOAA) dose-dependently decreases the stroma of C6 neuroastrocytoma cells. Treatment with aminooxyacetic acid hemihydrochloride greatly raised the proportion of cells in the G0/G1 phase of the cervix, and dramatically lowered the proportion of cells in the purified AS phase and G2/M phase. Treatment with hemihydrochloride resulted in a considerable reduction in the number of cells in the cell division phase. Aminoacetic acid hemihydrochloride considerably raised the percentage of early cells and surviving cells. Treatment of cells with 1 mM or 5 mM aminooxyacetic acid hemihydrochloride lowers cell senescence [1]. Glutamine-dependent cell lines revealed a stronger inhibitory effect on cell development by ammonia oxygen hemihydrochloride (AOA) than glutamine-dependent cells [3].
|
|---|---|
| ln Vivo |
GABA accumulates in the cerebellum and throughout the brain fairly quickly at first; five minutes after ethylene oxide hemihydrochloride (AOAA) injection, there is a noticeable increase in GABA levels. After 2 to 6 hours of ethylene oxide hemihydrochloride, the rapid final accumulation gradually slows down and achieves maximum levels (400 to 600% of control levels). Within twenty-four hours, GABA levels rose by about 250%. The amount of GABA increases by about 250% after 2–6 hours. the seizures were stopped. The 24-hour withdrawal of ammonia hemihydrochloride is identical to that which is required for expectant mothers [2].
|
| References |
|
| Additional Infomation |
(aminooxy)acetic acid hemihydrochloride is the hemihydrochloride salt of (aminooxy)acetic acid. It is a malate-aspartate shuttle (MAS) inhibitor which also inhibits the GABA degradating enzyme 4-aminobutyrate aminotransferase and cystathionine beta-synthetase. It contains an (aminooxy)acetate.
|
| Molecular Formula |
C4H11CLN2O6
|
|---|---|
| Molecular Weight |
218.5929
|
| Exact Mass |
218.03
|
| CAS # |
2921-14-4
|
| Related CAS # |
Aminoxyacetic acid;645-88-5
|
| PubChem CID |
2723609
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
326.7ºC at 760 mmHg
|
| Melting Point |
156 °C (dec.)(lit.)
|
| Flash Point |
151.4ºC
|
| Vapour Pressure |
4.24E-05mmHg at 25°C
|
| LogP |
0.125
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
13
|
| Complexity |
52.8
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KBXIJIPYZKPDRU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/2C2H5NO3.ClH/c2*3-6-1-2(4)5;/h2*1,3H2,(H,4,5);1H
|
| Chemical Name |
2-aminooxyacetic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~1143.64 mM)
H2O : ~100 mg/mL (~914.91 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (19.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (19.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (19.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 130 mg/mL (1189.39 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5748 mL | 22.8739 mL | 45.7477 mL | |
| 5 mM | 0.9150 mL | 4.5748 mL | 9.1495 mL | |
| 10 mM | 0.4575 mL | 2.2874 mL | 4.5748 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
